Aspirin Significantly Reduces Recurrence Risk in Colorectal Cancer Patients with Specific Genetic Markers

A recent clinical trial led by researchers from Karolinska Institutet has demonstrated that a low dose of aspirin can halve the chance of cancer recurrence in patients with colorectal cancer, particularly those whose tumors carry a certain genetic mutation. This groundbreaking study, published in The New England Journal of Medicine, involved over 3,500 patients across Scandinavia. Participants with tumors showcasing a mutation in the PIK3 signaling pathway—a genetic alteration present in approximately 40% of colorectal cancer cases—were randomly assigned to receive 160 mg of aspirin daily or a placebo for three years following surgery. Results revealed that those with the mutation who took aspirin experienced a 55% reduction in recurrence risk compared to the control group. The findings suggest that aspirin's protective effect may be due to its ability to reduce inflammation, inhibit platelet function, and suppress tumor growth, thereby creating a less favorable environment for cancer cells. This research exemplifies the potential of precision medicine, using genetic information to tailor treatment strategies. Aspirin's affordability and widespread availability make it a promising adjunct in colorectal cancer management, especially for genetically defined patient subgroups. The study highlights the importance of genetic testing in guiding personalized treatments that can improve outcomes and reduce suffering for patients worldwide.